碩世生物(688399.SH):擬追加捐贈不超300萬的新型冠狀病毒核酸檢測試劑及儀器
格隆匯2月19日丨碩世生物(688399.SH)公佈,自新型冠狀病毒肺炎疫情發生以來,公司積極投身疫情防控工作,為抗擊疫情貢獻力量,2020年1月27日公司第一屆董事會第十四次會議審議通過了《關於公司對外捐贈的議案》,決定向疾控系統和醫療機構捐贈累計價值1000萬人民幣的新型冠狀病毒核酸檢測試劑及儀器。上述捐贈產品已全部到達疾控系統和醫療機構。
基於目前疫情防控形勢,2020年2月18日召開第一屆董事會第十五次會議以九票同意、零票反對、零票棄權審議通過了《關於公司追加對外捐贈的議案》,擬向疾控系統和醫療機構追加捐贈累計價值不超過300萬人民幣的新型冠狀病毒核酸檢測試劑及儀器,用於新型冠狀病毒檢測。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.